NKTR — Nektar Therapeutics Share News
0.000.00%
Last trade - 00:00- $1.32bn
- $692.66m
- $55.23m
Brief: Nektar Therapeutics Rezpegaldesleukin Demonstrates Durability And Deepening Of Response Through One Year Of Treatment
U.S. STOCKS ON THE MOVEx-Microsoft, 3M, Twilio
U.S. STOCKS ON THE MOVEx-Microsoft, Nike, Nektar Therapeutics
Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says
U.S. STOCKS ON THE MOVE-3M, CoreCivic, Almonty Industries
Nektar gains; jury finds Lilly breached contract in drug partnership dispute
Brief: Nektar Therapeutics - Jury Finds Lilly Breached Implied Covenant Of Good Faith In License Agreement
Brief: Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP-Health Catalyst, Nektar Therapeutics, TIC Solutions
U.S. STOCKS ON THE MOVE-Sun Communities, Cisco Systems, Paysafe
U.S. STOCKS ON THE MOVE-Fox, Sun Communities, Reddit, drone firms
U.S. STOCKS ON THE MOVE-Boost Run, Nektar Therapeutics, Swarmer
Nektar Therapeutics falls on quarterly revenue miss
Nektar Therapeutics reports results for the quarter ended June 30 - Earnings Summary
Nektar Therapeutics Q2 revenue falls, net loss narrows
Brief: Nektar Therapeutics Q2 EPS USD -1.23
Brief: Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Nektar Therapeutics Announces Start Of Phase 3 Zenith Ad Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin In Moderate-To-Severe Atopic Dermatitis
Brief: Nektar Therapeutics May Offer And Sell Common Stock Up To $150 Million - SEC Filing